The congress will be held on October 2-5, 2016 in Brussels, Belgium.

Dr. Salvatore Gueli Alletti, a gynecologic oncologist at the Gemelli Hospital of the Catholic University of the Sacred Heart in Rome, Italy, will give a lecture on the Senhance system. The lecture, titled, “Initial clinical experience with a surgical robotic system incorporating laparoscopic motion, force sensing instrumentation, and eye-sensing camera control,” will be held on October 5, 2016, at 11:30am CEST.

“With the Senhance, gynecologic applications have become one of the leading procedural focuses for TransEnterix,” said Todd M. Pope, President and CEO of TransEnterix.

”Gynecologists are welcoming this new robotic option with haptic force feedback, eye-sensing camera control, and compelling procedural costs. We look forward to further showcasing the Senhance’s unique features at this year’s congress.”

The Senhance will be available for surgeon evaluations at the congress. The Senhance carries the CE Mark for use in general surgery, gynecology, urology and thoracic surgery. TransEnterix is actively preparing a submission for U.S. FDA Clearance for the Senhance.

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options.

 The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control.

The company is also developing the SurgiBot System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States.